drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (autologous TIL therapy)
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) cell therapy in which a patient’s tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor neoantigens via TCR–MHC and mediate cytotoxic CD8+ activity against cancer cells.
nci_thesaurus_concept_id
C200139
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs GT201 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-infiltrating T cells are isolated from the patient’s tumor, expanded ex vivo, and reinfused to recognize tumor neoantigens via native TCR–MHC interactions, leading to cytotoxic CD8+ T-cell–mediated killing of cancer cells and cytokine-driven antitumor activity.
drug_name
GT201
nct_id_drug_ref
NCT06235242